Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends to discuss these data with the U.S. Food and Drug Administration (FDA) and to submit a supplemental New Drug Application (sNDA) seeking […]
Tag: circadian regulator
Vanda Loses Patents on Hetlioz Sleep Drug
Vanda Pharmaceuticals Inc. responded to the ruling in its Hetlioz® Abbreviated New Drug Application appeal. A three-judge panel of the United States Court of Appeals for the Federal Circuit issued a written opinion that affirmed a December 13, 2022, decision of the United States District Court for the District of Delaware, which held that […]










